Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 4/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.45 |
| ▸ | POLA1 | P09884 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4588054 | 1.00 | ESR2 (0.45) | ESR2ESR1POLA1MTNR1AMTNR1B | |
| SCHEMBL4587928 | 0.88 | ESR2 (0.59) | ESR2ESR1 | |
| SCHEMBL6228937 | 0.88 | ESR2 (0.59) | ESR2ESR1 | |
| SCHEMBL6228939 | 0.88 | ESR2 (0.59) | ESR2ESR1 | |
| SCHEMBL4587924 | 0.88 | ESR2 (0.59) | ESR2ESR1 | |
| SCHEMBL6536200 | 0.83 | ESR1 (0.46) | ESR2ESR1POLA1MTNR1AMTNR1B | |
| SCHEMBL4589680 | 0.74 | LMNA (0.57) | ESR2ESR1OPRM1CYP2C19CYP3A4 | |
| SCHEMBL4589686 | 0.74 | LMNA (0.57) | ESR2ESR1OPRM1CYP2C19CYP3A4 | |
| SCHEMBL4588110 | 0.71 | ESR2 (0.67) | ESR2ESR1CYP2C9CYP2C19 | |
| SCHEMBL8048886 | 0.68 | PPARD (0.42) | ESR2ESR1POLA1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414043-B2 | 9-α-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2008-08-19 | — | — | US | disclosed |
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | KOSEMUND DIRK | 2008-06-05 | — | — | US | disclosed |
| EP-1517914-B1 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1517914-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | Schering Aktiengesellschaft (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | SCHERING AG (DE) | 2004-05-06 | — | — | US | disclosed |
| WO-2003104253-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132476-A1 | SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS | ESRRA, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885POLA1 1723/4885 |
| US-20040087565-A1 | 9-alpha-substituted estratrienes as selectively active estrogens | ESRRA, ESR2, HSD17B11 | ESR2 2/4885ESR1 7/4885POLA1 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.